GlassScriptPhysician profile
Eric Scott Guglielmo
NPI 1093866840
$655.40
in general payments reported to CMS, 2019-2025
11 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $79.83 · 2021: $20.36 · 2024: $136 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $187.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $138.68 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $60.01 | 2025 | |
| Genentech USA, INC. | $56.64 | 2024-2025 | Susvimo, Vabysmo |
| Astellas Pharma US INC | $54.74 | 2024-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $47.64 | 2025 | Iluvien |
| Apellis Pharmaceuticals, INC. | $44.65 | 2024-2025 | Syfovre |
| Sandoz INC. | $29.46 | 2024 | Cimerli |
| Eyepoint US, INC. | $20.36 | 2021 | |
| Allergan, INC. | $15.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,803.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Guglielmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.